Moexipril in arterial hypertension treatment among postmenopausal women with osteoporosis

Aim. To study effectiveness and safety of long-term monotherapy with АСГ inhibitor moexipril, as well as its combination with diuretic hydrochlorthiazide (HCT), in postmenopausal women with arterial hypertension (AH). Material and methods. In total, 38 women with postmenopause duration of 5 years and longer, aged 58-89 years, with untreated or treated ineffectively Stage I-II AH, and postmenopausal femoral osteoporosis, were followed up for 3 three years. Intervention group (n = 19) received moexipril (7,5-15 mg/d), plus CHT (12,5-25 mg/d) if target blood pressure, BP (<140/90 mm Hg), was not achieved. Control group (n = 19) received any antihypertensive agents chosen by the physician, excluding moexipril and thiazide diuretics. Results. By Week 16 of the treatment, the whole intervention group achieved target BP levels, including 52,6% for moexipril monotherapy; target BP levels were maintained for at least 3 years of follow-up. In control group, by Week 16, target BP was achieved in all participants, including 56,2% for monotherapy; nevertheless, 3 years later, target BP was maintained in 12 out of 19 women. By Week 8, moexipril monotherapy in intervention group was associated with significant reduction in systolic and diastolic BP (SBP, DBP) levels in daytime, nighttime and 24 hours. Daytime SBP and DBP variability significantly reduced, morning SBP and DBP surge significantly decreased. Three years later, according to densitometry data, minimal femoral bone density decreased by 4,3% in intervention group, and by 9,9% in control group (p<0,05). Moexipril demonstrated very good (n = 14) and good (n = 5) tolerability Conclusion. Moexipril, as monotherapy and in combination with HCT, is a highly effective and safe agent for long-term AH treatment in postmenopausal women with osteoporosis.

1. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6): 1011-49.

2. Ощепкова Е.В., Рогозова А.Н., Варакин Ю.А. и др. Вариабельность артериального давления (по данным 24-часового мониторирования) при мягкой артериальной гипертониии. Тер архив 1994; 8:70-3.

3. Тхостова Э.Б., Прошин А.Ю., Белоусов Ю.Б. Гипотензивная эффективность Цинга (моксонидина) у больных с мягкой и умеренной гипертонией по данным суточного мониторирования артериального давления. Клин фарм тер 1998; 1:36-8.

4. Koch В., Stimpel M., Andersson O. Do hypertensive women respond differently to low dosages of moexipril and hydrochlorothiozide? Hypertension 1995; 25: 1383(abstract), 120.

5. Stimpel M., Koch B. Antihypertensive treatment in post-menopausal women with hypertension and obesity: moexipril versus atenolol. Am J Hypertens 1996; 9(Suppl) Abs, N 17.

6. Stimpel V., Pruesse D.I. Efficacy and safety of moexipril and nitrendipine in postmenopausal women. Poster presentation, Abstracts 2nd International Symposium "Women's health and Menopause". Florence, Italy 1996; 60.

7. White W.B., Fox A., Stimpel M. Long term efficacy and safety of moexipril in the treatment of hypertension. J Hum Hypertens 1994;8:917-21.

8. White W.B., Stimpel M. Long term safety and efficacy of moexipril alone and in combina tion with hydrochlorothiazide in elderly patients with hypertension. J Hum Hypertens 1995; 9: 879-84.

9. Кобалава Ж.Д., Терещенко С.Н., Калинкин А.Л. Суточное мониторирование артериального давления: методические аспекты и клиническое значение. Под. ред. проф. B.C. Моисеева. Москва 1997; 32 с.

10. Fratolla A., Parati G., Cuspidi С. Prognostic value of 24-hour pressure variability. J Hypertens 1993; 11: 1133-7.

11. КобалаваЖ.Д., Котовская Ю.В. Мониторирование артериального давления: методические аспекты и клиническое значение. Москва «Сервье» 1999; 70 с.

12. Verdecchia P., Schillaci В., Guerrieri M., et al. Orcadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 8: 528-36.

13. Stimpel M., Bonn R., Koch B., Dickstein K. Pharmacology and clinical use of the new ACE inhiditor Moexipril. Cardiovasc Drug Rev 1995; 13(3): 211-9.

14. Hatton R., Stimpel M., Chambers T.J. The effect of angiotensin I and bradykinin in the presence and absence of moexiprilat, and angiotensin II, on osteoclast formation and activity. J Bone Mineral Res 1996; ll(Suppl): 185.

15. Stimpel M., Jee W.S.S., Ma Y., et al. Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the ACE inhibitor moexipril, 17-beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats. J Hypertens 1995; 13: 1852-6.